Your Twin learns with you

30% off annual Pro20% off monthly Pro

Ends in00h00m00s

David Mathieu

Professeur titulaire

Université de Sherbrooke
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Year:

2026

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

BACKGROUND: The efficacy of stereotactic radiosurgery (SRS) for the relief of trigeminal neuralgia (TN) is well established. Much less is known, however, about the benefit of SRS for multiple sclerosis (MS)–related TN (MS-TN). OBJECTIVE: To compare outcomes in patients who underwent SRS for MS-TN vs classical/idiopathic TN and identify relative risk factors for failure. METHODS: We conducted a retrospective, case-control study of patients who underwent Gamma Knife radiosurgery at our center for MS-TN between October 2004 and November 2017. Cases were matched 1:1 to controls using a propensity score predicting MS probability using pretreatment variables. The final cohort consisted of 154 patients (77 cases and 77 controls). Baseline demographics, pain characteristics, and MRI features were collected before treatment. Pain evolution and complications were obtained at follow-up. Outcomes were analyzed using the Kaplan-Meir estimator and Cox regressions. RESULTS: There was no statistically significant difference between both groups with regards to initial pain relief (modified Barrow National Institute IIIa or less), which was achieved in 77% of patients with MS and 69% of controls. In responders, 78% of patients with MS and 52% of controls eventually had recurrence. Pain recurred earlier in patients with MS (29 months) than in controls (75 months). Complications were similarly distributed in each group and consisted, in the MS group, of 3% of new bothersome facial hypoesthesia and 1% of new dysesthesia. CONCLUSION: SRS is a safe and effective modality to achieve pain freedom in MS-TN. However, pain relief is significantly less durable than in matched controls without MS.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (15)

Antonin LEVY, MD, PhD

Université Paris-Saclay

FRANCE
View details

Francis Jareczek

Assistant Professor

Medical College of Wisconsin

UNITED STATES
View details

Christian Iorio-Morin

Professeur agrégé neurochirurgie

Université de Sherbrooke

CANADA
View details

Manmeet Singh Ahluwalia

Professor of Translational Medicine

Florida International University Herbert Wertheim College of Medicine

UNITED STATES
View details

Jeremy G. Reynoso

University of California, Los Angeles

UNITED STATES
View details

David Baskin

Professor, Vice Chair, and Residency Program Director

Houston Methodist

UNITED STATES
View details

Phillip Bonney

Assistant Professor

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Christopher Cifarelli

Associate Professor of Neurosurgery & Radiation Oncology

West Virginia University Rockefeller Neuroscience Institute

UNITED STATES
View details

Paul Mulholland

Associate Professor

University College London

UNITED KINGDOM
View details

Chloe Dumot

Neurosurgeon

Hospices Civils de Lyon

FRANCE
View details

Georgios Mantziaris

University of Virginia

UNITED STATES
View details

John Anthony Jane Jr

Professor

Virginia Tech

UNITED STATES
View details

Robert Prins

Professor (with tenure)

Ronald Reagan UCLA Medical Center

UNITED STATES
View details

Denise Bernhardt

Klinikum rechts der Isar der Technischen Universität München

GERMANY
View details

David Tran

University of Southern California

UNITED STATES
View details